Golden State Equity Partners’s Jade Biosciences JBIO Stock Holding History

Golden State Equity Partners’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$246K	Buy	311 +10	+3%	+$5.1K	0.06%	314
2023 Q3	$143K	Hold	301	–	–	0.04%	325
2023 Q2	$181K	Hold	301	–	–	0.05%	350
2023 Q1	$212K	Buy	+301	New	+$250K	0.11%	195
2022 Q1	$385K	Buy	599 +144	+32%	+$55.9K	0.19%	128
2021 Q4	$188K	Buy	+455	New	+$230K	0.1%	163

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return